In Silico Design of Hemolysin Inhibitors

Staphylococcus haemolyticus strains are the second of the most frequently encountered Coagulase Negative Staphylococci that have been recognized as an emerging and important human pathogen causing serious infections such as endocarditis, urinary tract infections, septicemia, peritonitis, wound, bone and joint infections. Patients with the illnesses are usually immunocompromised, with indwelling or implanted foreign bodies . In Silico drug design represents a new approach for drug discovery and industry. This approach was used in this study to find multi-target inhibitors against the hemolysin proteins of the Staphylococcus haemolyticus which is considered the main virulence factor of this bacterium. One hundred thirty two samples were collected from wounds, ear swaps, blood cultures and from urine samples of Iraqi patients for bacterial identification from 1/12/2013 to 28/4/2014 period. Forty six of samples were diagnosed as Staphylococcus haemolyticus by biochemical tests. Almost all isolates had the ability to produce hemolysin at different degrees.